Curcumin Boosts up the Efficacy of Imatinib Mesylate in Chronic Myelogenic Leukemia Cell Line K-562 by Modulation of Various Markers

Mukherjee, Arup; Sarkar, Ruma; Mukherjee, Sutapa; Biswas, Jaydip; Roy, Madhumita

doi:10.20546/ijcmas.2016.512.026

Cited by 10 publications

(18 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wu et al [ 347 ] revealed the activities of CUR in K562 cells and estimated that CUR-mediated suppression of proliferation of K562 cells through p210 BCR-ABL downregulation, which further resulted in suppression of the Ras signal transduction cascade. In CML cells, Mukherjee et al [ 348 ] reported that CUR improved the efficacy of imatinib mesylate (IM). Various doses of IM (alone) or in combination with CUR (30 μM) were used to treat K562 cells.…”

Section: Anticancer Activity Of Curcumin Against Various Types Of mentioning

confidence: 99%

“…It was also exhibited by western blot analysis that when IM (alone) or acombination of IM and CUR was used, itdownregulated the expression of p210 BCR-ABL, heat shock protein 90 (Hsp90), survivin, and NF-κB subunits p65 and p50. Moreover, they reported that treatment with a combination of IM and CUR elevated the effects of caspase-3 , caspase-8 , and caspase -9 [ 348 ]. In a different study, Zhang et al [ 349 ] showed that a combination of CUR and phosphorothioate antisense oligonucleotides led to synergistic suppressive activities on K562 cell proliferation via downregulating Hsp90, NF-κB, and P210 BCR-ABL.…”

Section: Anticancer Activity Of Curcumin Against Various Types Of mentioning

confidence: 99%

See 1 more Smart Citation

Potential Role of Curcumin and Its Nanoformulations to Treat Various Types of Cancers

et al. 2021

View full text Add to dashboard Cite

Cancer is a major burden of disease globally. Each year, tens of millions of people are diagnosed with cancer worldwide, and more than half of the patients eventually die from it. Significant advances have been noticed in cancer treatment, but the mortality and incidence rates of cancers are still high. Thus, there is a growing research interest in developing more effective and less toxic cancer treatment approaches. Curcumin (CUR), the major active component of turmeric (Curcuma longa L.), has gained great research interest as an antioxidant, anticancer, and anti-inflammatory agent. This natural compound shows its anticancer effect through several pathways including interfering with multiple cellular mechanisms and inhibiting/inducing the generation of multiple cytokines, enzymes, or growth factors including IκB kinase β (IκKβ), tumor necrosis factor-alpha (TNF-α), signal transducer, and activator of transcription 3 (STAT3), cyclooxygenase II (COX-2), protein kinase D1 (PKD1), nuclear factor-kappa B (NF-κB), epidermal growth factor, and mitogen-activated protein kinase (MAPK). Interestingly, the anticancer activity of CUR has been limited primarily due to its poor water solubility, which can lead to low chemical stability, low oral bioavailability, and low cellular uptake. Delivering drugs at a controlled rate, slow delivery, and targeted delivery are other very attractive methods and have been pursued vigorously. Multiple CUR nanoformulations have also been developed so far to ameliorate solubility and bioavailability of CUR and to provide protection to CUR against hydrolysis inactivation. In this review, we have summarized the anticancer activity of CUR against several cancers, for example, gastrointestinal, head and neck, brain, pancreatic, colorectal, breast, and prostate cancers. In addition, we have also focused on the findings obtained from multiple experimental and clinical studies regarding the anticancer effect of CUR in animal models, human subjects, and cancer cell lines.

show abstract

Section: Anticancer Activity Of Curcumin Against Various Types Of mentioning

confidence: 99%

Section: Anticancer Activity Of Curcumin Against Various Types Of mentioning

confidence: 99%

Potential Role of Curcumin and Its Nanoformulations to Treat Various Types of Cancers

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Curcumin enhanced the sensitivity of K562 cells to this drug by downregulation of P‐gp. Also, combination of curcumin and imatinib increased apoptosis induction in the cells by reducing expression of NF‐κB, surviving, HSP90 , Bcl2 genes and increasing caspase activity (Mukherjee, Sarkar, Mukherjee, Biswas, & Roy, 2016; Peng et al, 2012).…”

Section: Curcumin Overcomes Drug Resistancementioning

confidence: 99%

“…Curcumin enhanced the sensitivity of K562 cells to this drug by downregulation of P-gp. Also, combination of curcumin and imatinib increased apoptosis induction in the cells by reducing expression of NF-κB, surviving, HSP90, Bcl2 genes and increasing caspase activity(Mukherjee, Sarkar, Mukherjee, Biswas, & Roy, 2016;Peng et al, 2012).F I G U R E 1 0 Co-treatment with curcumin and chemotherapy drugs. Curcumin increases chemosensitivity of anticancer drugs by changing different signaling pathway.…”

mentioning

confidence: 99%

Curcumin effect on cancer cells' multidrug resistance: An update

Keyvani‐Ghamsari

Khorsandi

Gul

2020

Phytotherapy Research

View full text Add to dashboard Cite

Chemotherapy is one of the main methods for cancer treatment. However, despite many advances in the design of anticancer drugs, their efficiency is limited due to their high toxicity and resistance of cells to chemotherapeutic drugs. In order to improve the cancer therapy, it is essential to use the compounds that can overcome drug resistance and increase treatment efficiency. Researchers have studied the effects of natural compounds for the controlling various drug resistance mechanisms. Curcumin is a natural phenolic compound which shows potent anticancer activities in different tumors, alone or as an adjuvant with other antitumor drugs to prevent or inhibit the survival and cancer progression by various mechanisms. The role of curcumin in overcoming drug resistance was followed by reviewing different applications of curcumin in cancer therapy. Afterward, the clinical impacts of curcumin, role of curcumin in decreasing drug resistance in different cancer cells and its mechanisms were discussed. It has been demonstrated that curcumin regulates signaling pathways in cancer cells, reduces the expression of proteins related to drug resistance, and increases the performance of antitumor drugs at various levels. Curcumin reverses multidrug resistance mechanisms and increases sensitivity of resistance cells to chemotherapy. This review mainly focuses on different mechanisms of drug resistance and curcumin as a nontoxic natural substance to eliminate the effects of drug resistance through modulation and controlling cell resistance pathways and eventually suggests curcumin as a potent chemosensitizer in cancers.

show abstract

“…The cytokine levels (TNF-α, IL-6, IL-8, and IL-10) were estimated using ELISA kits as described previously (Mukherjee et al, 2016).…”

Section: Enzyme-linked Immunosorbent Assaymentioning

confidence: 99%

Curcumin May Enhance the Efficacy of Anti-Leukemia Drugs in Myeloid Leukemia

Mukherjee¹,

Mukherjee²,

Mukherjee³

et al. 2018

Int.J.Curr.Microbiol.App.Sci

View full text Add to dashboard Cite

Curcumin Boosts up the Efficacy of Imatinib Mesylate in Chronic Myelogenic Leukemia Cell Line K-562 by Modulation of Various Markers

Cited by 10 publications

References 28 publications

Potential Role of Curcumin and Its Nanoformulations to Treat Various Types of Cancers

Potential Role of Curcumin and Its Nanoformulations to Treat Various Types of Cancers

Curcumin effect on cancer cells' multidrug resistance: An update

Curcumin May Enhance the Efficacy of Anti-Leukemia Drugs in Myeloid Leukemia

Contact Info

Product

Resources

About